Bristol-Myers (BMY) Q4 Earnings Beat Estimates
Bristol-Myers Squibb Company BMY is a New York-based major producer and distributor of pharmaceuticals and other healthcare related products. The company’s key oncology products include Opdivo, Sprycel, Yervoy and Empliciti. Other than oncology, the company is focused on immunology and cardiovascular drugs like Orencia and Eliquis. It also markets drugs for HBV and HCV like Baraclude and Daklinza. The company’s virology portfolio comprises products like Reyataz and the Sustiva franchise.
Bristol-Myers is also active on partnership front and pursue strategic acquisitions across therapeutic areas including immunoscience, oncology, fibrosis and genetically defined diseases.
However, like many of its peers, Bristol-Myers is facing generic competition for several of its key products. Moreover, its HIV and HCV businesses are under competitive pressure. In this scenario, investor focus remains on company’s high-profile immuno-oncology drug, Opdivo, apart from the usual top-and bottom-line numbers.
Bristol-Myers has a mixed record of earnings surprises in the recent quarters. The company’s earnings surpassed expectations in three of the last four quarters, with an average positive surprise of 2.72%
Currently, Bristol-Myers has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Bristol-Myers beats on fourth-quarter 2017 earnings. The company reported EPS of 68 cents while our consensus called for EPS of 67 cents.
Revenues: Moreover, revenues were above expectations. Bristol-Myers posted revenues of $5.45 billion, compared to our consensus estimate of $5.31 billion.
2018 Guidance: Bristol-Myers provided its earnings outlook for 2018. The company expects earnings in the range of $3.15 to $3.30 per share. The Zacks Consensus Estimate for earnings stands at $3.21 per share.
Pre-Market Trading: Shares are down 3.2% in pre-market trading.
Check back later for our full write up on this BMY earnings report later!
Bristol-Myers Squibb Company Price and EPS Surprise
Bristol-Myers Squibb Company Price and EPS Surprise | Bristol-Myers Squibb Company Quote
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
